Related Experiment Videos
In vivo activity of cefodizime
Abstract:
Cefodizime has been shown to possess high in vivo antibacterial activity in a variety of experimental infection models involving different body systems and animal species: systemic infections, pneumonia and urinary tract infections in normal mice, intrauterine infections in normal rats, and meningitis in normal rabbits, as well as systemic infections in immunosuppressed animals. Most investigations found that the therapeutic efficacy of cefodizime frequently exceeded the one expected from its in vitro values and in many cases compared favorably with those of other cephems, even when the in vitro susceptibility of the infecting organism to these drugs was markedly higher. These findings have been attributed either to the superior kinetic profile of cefodizime--prolonged serum half-life and excellent tissue penetration with long-lasting levels--or to a synergy between its high bactericidal activity and host defence mechanisms. The parallel consideration of the MIC90 values of cefodizime and the pharmacokinetic profile of this agent in humans indicate that the vast majority of the relevant respiratory and urinary pathogens are covered by once-a-day cefodizime dosage regimens of either 1 or 2 g.
Insights
Cefodizime demonstrates potent in vivo antibacterial activity, often surpassing in vitro predictions and comparing favorably to other cephems. Its efficacy is linked to favorable pharmacokinetics and synergy with host defenses.
Area of Science:
- Pharmacology
- Infectious Diseases
- Microbiology
Background:
- Cefodizime is a cephalosporin antibiotic.
- Understanding its in vivo efficacy is crucial for clinical application.
Purpose of the Study:
- To evaluate the in vivo antibacterial activity of cefodizime.
- To compare its efficacy with other cephalosporins.
- To explore the reasons behind its observed therapeutic effects.
Main Methods:
- Experimental infection models in various animal species (mice, rats, rabbits).
- Assessment of cefodizime's efficacy in systemic, respiratory, and urinary tract infections.
- Comparison of in vivo efficacy with in vitro susceptibility data.
Main Results:
- Cefodizime exhibited high in vivo antibacterial activity across multiple infection models.
- Therapeutic efficacy often exceeded in vitro expectations and compared favorably to other cephems.
- Findings attributed to superior pharmacokinetics (long half-life, tissue penetration) and synergy with host defenses.
Conclusions:
- Cefodizime possesses significant in vivo antibacterial properties.
- Its pharmacokinetic profile and interaction with host immunity contribute to its effectiveness.
- Once-daily dosing of 1-2g is likely effective against common respiratory and urinary pathogens based on MIC90 and human pharmacokinetics.